Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication

Drugs -- Real World Outcomes
Javier Cid RuzafaVera Ehrenstein

Abstract

A Direct Healthcare Professional Communication (DHPC) sent in Denmark on 11 August 2011 provided information on new pioglitazone labelling and guidance on monitoring treatment effectiveness. We describe pioglitazone use in Denmark after the DHPC, estimate the incidence of heart failure (HF), quantify pioglitazone cessation following a diagnosis of bladder cancer (BC) or uninvestigated macroscopic haematuria, and describe glycated haemoglobin (HbA1c) values. This was a cohort study. From Danish population-based registries, cohorts of type 2 diabetes mellitus incident or prevalent users of pioglitazone or insulin in 2011-2015 were created. Patient characteristics, treatment patterns, laboratory results (available for a regional subset of the population), and incidence rates of HF and BC were estimated. There were 80 pioglitazone and 17,699 insulin incident users, 140 pioglitazone and 13,183 insulin prevalent users. There were no new BC cases among incident pioglitazone users, and < 5 new BC cases among prevalent pioglitazone users. Pioglitazone was rarely the first-line treatment. History of haematuria was documented in < 5 incident and 11 prevalent pioglitazone users. During follow-up, there were < 5 HF cases among 77 incident p...Continue Reading

References

Mar 24, 2000·Journal of Clinical Epidemiology·A Thornton, P Lee
Jun 15, 2011·Pharmacoepidemiology and Drug Safety·Kristian B FilionJames M Brophy
Jul 12, 2011·Central European Journal of Public Health·Nazish Siddiqi
Aug 4, 2011·Scandinavian Journal of Public Health·Carsten Bøcker Pedersen
Aug 4, 2011·Scandinavian Journal of Public Health·Elsebeth LyngeMatejka Rebolj
May 12, 2012·British Journal of Clinical Pharmacology·Li WeiIsla S Mackenzie
Jun 19, 2012·Diabetes Research and Clinical Practice·Zhaowei ZhuChen Xu
Oct 19, 2012·The Journal of Clinical Endocrinology and Metabolism·Christopher Ll MorganCraig J Currie
Dec 4, 2012·Clinical Epidemiology·Sigrun Alba JohannesdottirHenrik Toft Sørensen
Jan 29, 2013·Diabetic Medicine : a Journal of the British Diabetic Association·M FerwanaM H Murad
Jun 27, 2014·European Journal of Epidemiology·Morten SchmidtHenrik Toft Sørensen
Dec 8, 2014·Diabetologia·Daniel LevinUNKNOWN Diabetes and Cancer Research Consortium
Jul 22, 2015·JAMA : the Journal of the American Medical Association·James D LewisAssiamira Ferrara
Nov 26, 2015·Clinical Epidemiology·Morten SchmidtHenrik Toft Sørensen
Dec 1, 2015·Pharmacoepidemiology and Drug Safety·Jean-Luc Faillie, Dominique Hillaire-Buys
Sep 20, 2016·Pharmacoepidemiology and Drug Safety·Preeti Datta-NemdharryKatherine Donegan
Oct 30, 2016·Clinical Epidemiology·Diana Hedevang ChristensenReimar Wernich Thomsen
Nov 16, 2016·Clinical Epidemiology·Marit Eika JørgensenPeter Rossing
Jan 10, 2017·Pharmacoepidemiology and Drug Safety·Christian Hampp, Jennifer Pippins
Jun 18, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Elena FilipovaToni Vekov

❮ Previous
Next ❯

Citations

Aug 9, 2019·Open Forum Infectious Diseases·Meredith WoodwardWalter Straus

❮ Previous
Next ❯

Software Mentioned

PROactive
SAS

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

© 2021 Meta ULC. All rights reserved